Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCD1 | P51178 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | FGF1 | P05230 | 1/20 | 0.43 |
| ▸ | FGF2 | P09038 | 1/20 | 0.43 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
| ▸ | HLCS | P50747 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426309 | 0.99 | PLCD1 (0.49) | PLCD1F2TYMSFGF1FGF2 | |
| SCHEMBL29627228 | 0.98 | PLCD1 (0.47) | PLCD1F2TYMSFGF1FGF2 | |
| SCHEMBL14399749 | 0.92 | PLCD1 (0.47) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL9979889 | 0.92 | PLCD1 (0.48) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL12994951 | 0.92 | PLCD1 (0.48) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL14406729 | 0.92 | PLCD1 (0.48) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL28312091 | 0.91 | TYMS (0.52) | PLCD1F2TYMS | |
| SCHEMBL20126981 | 0.90 | PLCD1 (0.48) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL14370813 | 0.88 | PLCD1 (0.46) | PLCD1F2FGF1FGF2VEGFA | |
| SCHEMBL21909 | 0.88 | PLCD1 (0.48) | PLCD1F2FGF1FGF2VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518873-B | Optimized method for amplifying target nucleic acid and application | 上海羿鸣生物科技有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-115820595-A | Optimized polymerase for amplifying target nucleic acid, composite system and application | 南京君华基因科技有限公司 | 2023-03-21 | — | — | CN | claimed |
| WO-2022232087-A1 | METHODS FOR PERFORMING IN VITRO TRANSCRIPTION USING dUTP | NUTCRACKER THERAPEUTICS, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| CN-111454926-B | Optimized polymerase for amplifying target nucleic acid, composite system and application | 南京君华基因科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-115058469-A | Method for labeling 3' -end biotin of short DNA fragment | 深圳大学 | 2022-09-16 | — | — | CN | claimed |
| EP-4716752-A2 | ENDONUCLEASE SYSTEMS | Metagenomi, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12584169-B2 | Compositions and methods for improving sample identification in indexed nucleic acid libraries | ILLUMINA, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4709863-A2 | SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCES | Metagenomi, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705464-A2 | BASE EDITING ENZYMES | Metagenomi, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2026044118-A1 | ENDONUCLEASE SYSTEMS | METAGENOMI, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4684009-A1 | IMPROVED METHODS AND COMPOSITIONS FOR CRISPR INTERFERENCE AND ACTIVATION | Algen Biotechnologies, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4677092-A2 | CLASS 2, TYPE V CRISPR SYSTEMS | Metagenomi, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2022056324-A1 | BASE EDITING ENZYMES | METAGENOMI IP TECHNOLOGIES, LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022056301-A1 | BASE EDITING ENZYMES | METAGENOMI IP TECHNOLOGIES, LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022046662-A1 | SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCES | METAGENOMI IP TECHNOLOGIES, LLC (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220065849-A1 | IDENTIFICATION OF COGNATE PAIRS OF LIGANDS AND RECEPTORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-03-03 | — | — | US | disclosed |
| US-20210180118-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR IMMUNE REPERTOIRE SEQUENCING | ARCHERDX, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210054435-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION | ArcherDX, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20180155767-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR IMMUNE REPERTOIRE SEQUENCING | ArcherDX, Inc. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180127806-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION | ArcherDX, Inc. (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155767-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR IMMUNE REPERTOIRE SEQUENCING | TLR9, HAVCR2, IGSF11 | PLCD1 2982/4885F2 3361/4885TYMS 755/4885 |
| US-12584169-B2 | Compositions and methods for improving sample identification in indexed nucleic acid libraries | DCLRE1B, RNGTT, FEN1 | PLCD1 1925/4885F2 3840/4885TYMS 391/4885 |
| US-20210180118-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR IMMUNE REPERTOIRE SEQUENCING | TLR9, HAVCR2, IGSF11 | PLCD1 2982/4885F2 3361/4885TYMS 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.